Skip Nav Destination September 26, 2022 COVID-19 infection did not exacerbate the risk for venous thromboembolism (VTE) among patients with sickle cell disease (SCD), according to data from a retrospective study published in Blood…
Key Points. In relapsed MCL, venetoclax-ibrutinib achieves 7-year PFS of 30%, TTF of 39%, OS of 43% and durable remissions in 10/17 respondersElective trea
Tisagenlecleucel responses in patients with r/r FL remain highly durable a year after primary analysis; no new safety signals were observed.Low levels of L
Key Points. Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor siteMore
An asymptomatic 55-year-old woman presented with thrombocytosis discovered 2 years earlier. Laboratory testing revealed the following: hemoglobin 13.1 g/dL, red blood cell count 5.04 ×…
Neoantigens arising from recurrent AML mutations are immunogenic and represent novel immunotherapeutic targets.IDH2R140Q-specific T cells can selectively e
Using 4 illustrative cases, Treon and colleagues discuss their approach to therapy in patients with Waldenström macroglobulinemia (WM) based on genomic pro
In this issue of Blood Advances, Akahoshi et al1 provided evidence that higher serum concentrations of suppression of tumorigenicity 2 (ST2) and regenerati
In this issue of Blood Advances, Lineburg et al describe the interplay between graft-versus-host disease (GVHD), hematopoietic stem cell (HSC) engraftment,
Relapsed or refractory acute myeloid leukemia (AML) has an extremely poor prognosis because of intrinsic chemotherapy resistance and high rates of relapse,
